Table 4.

Proportion, phenotype, and fractions of tumor-reactive lymphocytes of large-scale expanded TIL from melanoma-invaded lymph nodes from 31 patients.

Patients	Relapsed	Number of infused TIL × 109		% CD3/CD4-positiveb		% CD3/CD8-positiveb		Ratio of CD4/CD8		% IFN-γ-positive lymphocytesc
		E1a	E2	E1	E2	E1	E2	E1	E2	E1a	E2
M88*	+	6	0.7	27	39	71	59	0.4	0.7	ND	0.4
M98*	+	33.5	21.4	85	93	14	7	6.1	13.3	NA	NA
M99	−	1.7	0.8	60	33	38	61	1.6	0.5	NA	NA
M100	+	11.6	6	94	95	5	4	18.8	23.8	NA	NA
M103*	+	7.65	27.6	43	57	66	58	0.7	1.0	NA	NA
M110	−	1.13	1.05	78	84	18	18	4.3	4.7	0.0	0.0
M113	−	10	11.2	36	75	75	28	0.5	2.7	10.3	0.8
M117	+	1.4	32	30	3	70	97	0.4	0.03	ND	2.50
M125	−	12	13.2	71	65	30	36	2.4	1.8	0.0	2.4
M126	−	10.2	10.8	55	39	40	56	1.4	0.7	NA	NA
M132	−	8.3	12.2	39	20	58	80	0.7	0.3	0.0	0.0
M134	+	13.5	9	55	62	45	38	1.2	1.6	0.7	0.0
M139*	−	12.3	13.4	53	60	42	34	1.3	1.8	NA	NA
M148	−	15.2	3.1	39	46	57	55	0.7	0.8	NA	NA
M158	−	8	10.2	30	31	70	63	0.4	0.5	0.0	0.0
M170*	+	9	0.53	30	32	67	67	0.4	0.5	1.2	ND
M171	−	10	12	48	42	52	58	0.9	0.7	0.0	0.0
M174*	+	9.5	4.7	80	70	20	30	4.0	2.3	NA	NA
M180*	+	5.5	3.5	29	19	68	80	0.4	0.2	NA	NA
M182	+	0.576	3.1	87	25	13	71	6.7	0.4	0.0	0.7
M187	+	8	10	16	24	86	76	0.2	0.3	2.9	0.4
M192	−	10	15.6	49	82	51	18	1.0	4.6	NA	NA
M193	−	12	5.2	14	27	86	73	0.2	0.4	3.5	4.0
M196*	−	8.6	14	40	22	58	74	0.7	0.3	1.0	0.0
M197*	+	14	1	48	32	52	68	0.9	0.5	2.9	0.0
M199	−	5	3.3	25	14	75	86	0.3	0.2	2.7	2.4
M204	−	9.5	16.5	92	88	8	17	11.5	5.2	0	3.4
M209*	−	6.8	6.2	63	71	36	29	1.8	2.4	NA	NA
M212	−	7.8	11	52	33	47	57	1.1	0.6	0.4	1.0
M213*	+	9.1	8.5	24	24	76	72	0.3	0.3	NA	NA
M215*	+	8.8	5.5	45	68	46	31	1.0	2.2	NA	NA

*Melanoma patients bearing only one metastatic lymph node.

^aE1 and E2 were TIL populations obtained and reinjected to the patient from, respectively, the first and the second ex  vivo expansions.

^bPercentages of CD-positive TIL were estimated by membrane labeling. Cells were analyzed on a FACScan.

^cPercentages of IFN-γ secreting TIL were estimated by intracellular labeling. TIL were stimulated 6 h by autologous melanoma cells in presence of brefeldin A.

Then, cells were fixed, permeabilized, stained for cytokine production, and analyzed on a FACSCalibur.

^dRelapse of patients ((−): patients who relapsed; (+): patients who did not relapse).